10x Genomics, Inc. (TXG)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-03-25

Key Insights

  • The CEO Serge Saxonov sold a total of 15,000 shares of 10x Genomics Class A common stock on March 23 and March 24, 2026, indicating some insider selling activity.
  • Saxonov holds a significant beneficial ownership stake in 10x Genomics, including direct ownership of over 1.1 million Class A shares and indirect ownership through various trusts and irrevocable trusts.
  • The filing discloses details on Saxonov's Class B common stock holdings, which are convertible to Class A shares and represent significant voting power.
Filing tone (AI): Neutral
View Original Filing →
Annual Report Filed: 2026-02-13

Key Insights

  • 10x Genomics reported strong revenue growth of 25% year-over-year in 2025, driven by continued demand for its product and service offerings.
  • The company's gross margin improved by 2 percentage points in 2025, indicating improved operational efficiency and cost control.
  • 10x Genomics provided a positive outlook for 2026, forecasting 18-22% revenue growth and stable profitability, though the acquisition of Scale BioScience introduces some uncertainty.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new 10x Genomics, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.